© Springer International Publishing Switzerland 2016
Ton J. Cleophas and Aeilko H. ZwindermanSPSS for Starters and 2nd Levelers10.1007/978-3-319-20600-4_23

23. Interaction, Random Effect Analysis of Variance (40 Patients)

Ton J. Cleophas1, 2  and Aeilko H. Zwinderman2, 3
(1)
Department Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands
(2)
European College Pharmaceutical Medicine, Lyon, France
(3)
Department Biostatistics, Academic Medical Center, Amsterdam, The Netherlands
 

1 General Purpose

In pharmaceutical research and development, multiple factors like age, gender, comorbidity, concomitant medication, genetic and environmental factors co-determine the efficacy of the new treatment. In statistical terms we say, they interact with the treatment efficacy.
Interaction is different from confounding. In a trial with interaction effects the parallel groups have similar characteristics. However, there are subsets of patients that have an unusually high or low response.
A211753_2_En_23_Figa_HTML.gif
The above figure shows the essence of interaction: the males perform better than the females with the new medicine, with the control treatment the opposite (or no difference between males and females) is true.

2 Schematic Overview of Type of Data File

A211753_2_En_23_Figb_HTML.gif

3 Primary Scientific Question

Are there not only independent effects of two predictors on the outcome, but also interaction effects between two predictors on the outcome.

4 Data Example

In a 40 patient parallel-group study of the effect of verapamil and metoprolol on paroxysmal atrial fibrillation (PAF) the possibility of interaction between gender and treatment on the outcome was assessed. The numbers of episodes of paroxysmal atrial tachycardias per patient, are the outcome variable. The entire data file is in extras.springer.com, and is entitled “chapter23interaction”. The first ten patients of the data file is given below.
PAF
Treat
Gender
52,00
,00
,00
48,00
,00
,00
43,00
,00
,00
50,00
,00
,00
43,00
,00
,00
44,00
,00
,00
46,00
,00
,00
46,00
,00
,00
43,00
,00
,00
49,00
,00
,00
PAF = outcome = numbers of episodes of PAF
treat = 0 verapamil, 1 metoprolol
gender = 0 female, 1 male

5 Data Summaries

Verapamil
Metoprolol
 
Males
52
28
 
48
35
 
43
34
 
50
32
 
43
34
 
44
27
 
46
31
 
46
27
 
43
29
 
49  +
25  +
 
464
302
766
Females
38
43
 
42
34
 
42
33
 
35
42
 
33
41
 
38
37
 
39
37
 
34
40
 
33
36
 
34  +
35  +
 
368
378
746
832
680
 
Overall, metoprolol seems to perform better. However, this is only true for one subgroup (males). The presence of interaction between gender and treatment modality can be assessed several ways: (1) t-tests (see Chapter 18, Statistics on a pocket calculator part one, Springer New York, 2011, from the same authors), (2) analysis of variance, and (3) regression analysis. The data file is given underneath.

6 Analysis of Variance

We will first perform an analysis of variance. Open the data file in SPSS.
For analysis the General Linear Model is required. It consists of four statistical models:
  • Univariate,
  • Multivariate,
  • Repeated Measures,
  • Variance Components.
We will use here Univariate.
Command:
  • Analyze….General Linear Model….Univariate Analysis of Variance …. Dependent: PAF….Fixed factors:treatment, gender….click OK.
Tests of Between-Subjects Effects
Dependent Variable: outcome
Source
Type III sum of squares
df
Mean square
F
Sig.
Corrected model
1327,200a
3
442,400
37,633
,000
Intercept
57153,600
1
57153,600
4861,837
,000
Treatment
577,600
1
577,600
49,134
,000
Gender
10,000
1
10,000
,851
,363
Treatment * gender
739,600
1
739,600
62,915
,000
Error
423,200
36
11,756
   
Total
58904,000
40
     
Corrected total
1750,400
39
     
aR Squared = ,758 (Adjusted R Squared = ,738)
The above table shows that there is a significant interaction between gender and treatment at p = 0,0001 (* is sign of multiplication). In spite of this, the treatment modality is a significant predictor of the outcome. In situations like this it is often better to use a socalled random effect model. The “sum of squares treatment” is, then, compared to the “sum of squares interaction” instead of the “sum of squares error”. This is a good idea, since the interaction was unexpected, and is a major contributor to the error, otherwise called spread, in the data. This would mean, that we have much more spread in the data than expected, and we will lose a lot of power to prove whether or not the treatment is a significant predictor of the outcome, episodes of PAF. Random effect analysis of variance requires the following commands:
Command:
  • Analyze….General Linear Model….Univariate Analysis of Variance …. Dependent: PAF….Fixed Factors: treatment…. Random Factors: gender….click OK
The underneath table shows the results. As expected the interaction effect remained statistically significant, but the treatment effect has now lost its significance. This is realistic, since in a trial with major interactions, an overall treatment effect analysis is not relevant anymore. A better approach will be a separate analysis of the treatment effect in the subgroups that caused the interaction.
Tests of between-subjects effects
Dependent Variable:outcome
Source
Type III sum of squares
df
Mean square
F
Sig.
Intercept
Hypothesis
57153,600
1
57153,600
5715,360
,008
Error
10,000
1
10,000a
   
Treatment
Hypothesis
577,600
1
577,600
,781
,539
Error
739,600
1
739,600b
   
Gender
Hypothesis
10,000
1
10,000
,014
,926
Error
739,600
1
739,600b
   
Treatment * gender
Hypothesis
739,600
1
739,600
62,915
,000
 
Error
423,200
36
11,756c
   
aMS (gender)
bMS (treatment * gender)
cMS (Error)
As a contrast test we may use regression analysis for these data. For that purpose we first have to add an interaction variable:
  • interaction variable = treatment modality * gender
  • (* = sign of multiplication).
Underneath the first 10 patients of the above data example is given, now including the interaction variable.
PAF
Treat
Gender
Interaction
52,00
,00
,00
,00
48,00
,00
,00
,00
43,00
,00
,00
,00
50,00
,00
,00
,00
43,00
,00
,00
,00
44,00
,00
,00
,00
46,00
,00
,00
,00
46,00
,00
,00
,00
43,00
,00
,00
,00
49,00
,00
,00
,00
PAF = outcome = numbers of episodes of PAF
treat = o verapamil, 1 metoprolol
gender = 0 female, 1 male
interaction = interaction between treat and gender = treat * gender

7 Multiple Linear Regression

The interaction variable will be used together with treatment modality and gender as independent variables in a multiple linear regression model. For analysis the statistical model Linear in the module Regression is required.
Command:
  • Analyze….Regression….Linear….Dependent: PAF …Independent (s): treat, gender, interaction….click OK.
Coefficientsa
Model
Unstandardized coefficients
Standardized coefficients
t
Sig.
B
Std. error
Beta
1
(Constant)
46,400
1,084
 
42,795
,000
Treatment
−16,200
1,533
−1,224
−10,565
,000
Gender
−9,600
1,533
−,726
−6,261
,000
Interaction
17,200
2,168
1,126
7,932
,000
aDependent Variable: outcome
The above table shows the results of the multiple linear regression. Like with fixed effect analysis of variance, both treatment modality and interaction are statistically significant. The t-value-interaction of the regression = 7,932. The F-value-interaction of the fixed effect analysis of variance = 62,916 and this equals 7,9322. Obviously, the two approaches make use of a very similar arithmetic.
Unfortunately, for random effect regression SPSS has limited possibilities.

8 Conclusion

Interaction is different from confounding (Chap. 22). In a trial with interaction effects the parallel group characteristics are equally distributed between the groups. However, there are subsets of patients that have an unusually high or low response to one of the treatments. Assessments are reviewed.

9 Note

More background, theoretical, and mathematical information of interaction assessments is given in Statistics applied to clinical studies 5th edition, Chap. 30, Springer Heidelberg Germany, 2012, from the same authors.
SPSS for Starters and 2nd Levelers
ACoverHTML.html
A211753_2_En_BookFrontmatter_OnlinePDF.html
A211753_2_En_1_ChapterPart1.html
A211753_2_En_1_Chapter.html
A211753_2_En_2_Chapter.html
A211753_2_En_3_Chapter.html
A211753_2_En_4_Chapter.html
A211753_2_En_5_Chapter.html
A211753_2_En_6_Chapter.html
A211753_2_En_7_Chapter.html
A211753_2_En_8_Chapter.html
A211753_2_En_9_Chapter.html
A211753_2_En_10_Chapter.html
A211753_2_En_11_Chapter.html
A211753_2_En_12_Chapter.html
A211753_2_En_13_Chapter.html
A211753_2_En_14_Chapter.html
A211753_2_En_15_Chapter.html
A211753_2_En_16_Chapter.html
A211753_2_En_17_Chapter.html
A211753_2_En_18_Chapter.html
A211753_2_En_19_Chapter.html
A211753_2_En_20_Chapter.html
A211753_2_En_21_Chapter.html
A211753_2_En_22_Chapter.html
A211753_2_En_23_Chapter.html
A211753_2_En_24_Chapter.html
A211753_2_En_25_Chapter.html
A211753_2_En_26_Chapter.html
A211753_2_En_27_Chapter.html
A211753_2_En_28_Chapter.html
A211753_2_En_29_Chapter.html
A211753_2_En_30_Chapter.html
A211753_2_En_31_Chapter.html
A211753_2_En_32_Chapter.html
A211753_2_En_33_Chapter.html
A211753_2_En_34_ChapterPart2.html
A211753_2_En_34_Chapter.html
A211753_2_En_35_Chapter.html
A211753_2_En_36_Chapter.html
A211753_2_En_37_Chapter.html
A211753_2_En_38_Chapter.html
A211753_2_En_39_Chapter.html
A211753_2_En_40_Chapter.html
A211753_2_En_41_Chapter.html
A211753_2_En_42_Chapter.html
A211753_2_En_43_Chapter.html
A211753_2_En_44_Chapter.html
A211753_2_En_45_Chapter.html
A211753_2_En_46_Chapter.html
A211753_2_En_47_Chapter.html
A211753_2_En_48_Chapter.html
A211753_2_En_49_Chapter.html
A211753_2_En_50_Chapter.html
A211753_2_En_51_Chapter.html
A211753_2_En_52_Chapter.html
A211753_2_En_53_Chapter.html
A211753_2_En_54_Chapter.html
A211753_2_En_55_ChapterPart3.html
A211753_2_En_55_Chapter.html
A211753_2_En_56_Chapter.html
A211753_2_En_57_Chapter.html
A211753_2_En_58_Chapter.html
A211753_2_En_59_Chapter.html
A211753_2_En_60_Chapter.html
A211753_2_En_BookBackmatter_OnlinePDF.html